In the phase 3 AFFIRM trial, subcutaneous #risankizumab induction demonstrated superiority over placebo for achieving clinical remission and endoscopic response at week 12. #ACG2026
https://www.gastroenterologyadvisor.com/reports/subcutaneous-risankizumab-induction-crohn-disease/
